CERS News and Press, Cerus Corporation From 07/09/21

Cerus Corporation (NASDAQ:CERS) traded today at a new 52-week low of $5.11. Approximately 223,000 shares have changed hands today, as compared to an average 30-day volume of 1.6 million shares. Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. ...

Shares of Cerus Corporation (NASDAQ:CERS) traded at a new 52-week low today of $4.99. So far today approximately 223,000 shares have been exchanged, as compared to an average 30-day volume of 1.6 million shares. Cerus Corporation (NASDAQ:CERS) has potential upside of 8.5% based on a curr...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Cerus (CERS) announces an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT Fibrinogen Complex, the company’s pathogen reduced cryoprecipitated fibrinogen complex product.LifeSouth is the fifth production partner for I...

Partnership expands the initial launch into the Florida market Cerus Corporation (NASDAQ: CERS) announced today an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT ® Fibrinogen Complex, the company’s ...

Cerus Corporation continues to record growth, however, the market continues to overlook the company's progress and upside potential. The FDA compliance date in October should be a watershed event that should force the Street to acknowledge CERS. I discuss why I am still bullish an...

June 2021 also marks the 40 th anniversary of the first report of AIDS cases by the CDC Cerus Corporation (Nasdaq: CERS), a leader in safeguarding the global blood supply, is proud to announce its celebration of this year’s World Blood Donor Day. World Blood D...

The biotech industry has witnessed solid growth over the past year, in large measure attributable to the demand for drugs to fight COVID-19, among other diseases. The integration of technology and successful clinical trials of drugs for treating critical ailments have boosted Wall Street ...

Canadian Blood Services first to implement pathogen inactivation technology in Canada Cerus Corporation (Nasdaq:CERS) today announced its contract with Canadian Blood Services for the INTERCEPT Blood System for Platelets. Canadian Blood Services is one of Canada’s two...

Cerus Corporation (CERS) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Matt Notarianni - IR Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President o...